Clinical trial readout dates for argenx SE, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 2/3 EFG PH20 SC Active Idiopathic Inflammatory Myopathy; Myositis · NCT05523167 | July 2026 Primary data collected |
| Phase 2/3 Efgartigimod IV Generalized Myasthenia Gravis · NCT04833894 | March 2027 Ongoing |
| Phase 2 Efgartigimod PH20 SC Systemic Sclerosis (SSc) · NCT06655155 | March 2027 Ongoing |
| Phase 2 Efgartigimod PH20 SC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · NCT04280718 | April 2027 Ongoing |
| Phase 3 Efgartigimod PH20 SC Primary Sjogrens Disease · NCT06684847 | July 2027 Ongoing |
| Phase 2/3 Efgartigimod PH20 SC Generalized Myasthenia Gravis · NCT06392386 | September 2027 Recruiting |
| Phase 3 empasiprubart Chronic Inflammatory Demyelinating Polyneuropathy; CIDP · NCT06920004 | September 2027 Recruiting |
| Phase 2 Empasiprubart IV AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis (MG) · NCT07673627 | October 2027 Recruiting |
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 2 Empasiprubart IV Dermatomyositis; Myositis · NCT06284954 | November 2026 Ongoing |